Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine

Investigational New Drugs

Volumn 14, Issue 3, 1996, Pages 265-270

  Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

Clinical trials; Gemcitabine; Human tumor cloning assay (HTCA)

Indexed keywords

AGAR; ANTINEOPLASTIC AGENT; GEMCITABINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CLONOGENIC ASSAY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; EUROPE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; UNITED STATES;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; TUMOR STEM CELL ASSAY;

EID: 0029805907     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00194529     Document Type: Article

References (37)

1. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197:461-463, 1977
2. Salmon SE, Hamburger AW, Soehnlen B: Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. NEJM 298:1321-1327, 1978
3. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF: Prospective clinical trial of a human tumor cloning system. Cancer Res 43:1926-1931, 1983
4. Von Hoff DD, Sandbach JF, Clark GM, Turner JN, Forseth BF, Piccart MJ, Colombo N, Muggia FM: Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 82:110-116, 1990
5. Heinemann V, Hertel L, Grindey GB, Plunkett W: Comparison of the pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-b-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031, 1988
6. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422, 1990
7. Hanauske A-R, Degen D, Marshall MH, Hilsenbeck SG, Grindey GB, Von Hoff DD: Activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human tumor colony-forming units. Anticancer Drugs 3:143-146, 1992
8. Hanauske A-R, Hanauske U, Von Hoff DD: The human tumor cloning assay in cancer research and therapy: A review with clinical correlations. Curr Probl Cancer 9:1-50, 1985
9. Perez E, Eckardt J, Hilsenbeck S, Rothenberg M, Degen D, Von Hoff DD: Activity of cytotoxic agents against non-small cell lung cancer specimens using a human tumor cloning assay. Proc Am Assoc Cancer Res 35:203, 1994
10. Hanauske A-R, Von Hoff DD: Clinical correlations with the human tumor cloning assay. Cancer Invest 3:541-551, 1985
11. O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee PG, Tarassoff F, Von Hoff DD: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 30A(3):417-418, 1994
12. Brown T, O'Rourke T, Burris H, Kuhn J, Tarasoff P, Cagnola J, Rodriguez G, Von Hoff D: A phase I trial of gemcitabine (LY188011) administered intravenously every two weeks. Proc Am Soc Clin Oncol 10:115, 1991
13. Pollera CF, Ceribelli A, Crecco M, Calabresi F: Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5(2):182-184, 1994
14. Carmichael J, Possinger K, Philip P, Beykirch M, Kerr H, Walling J, Harris AL: Difluorodeoxycytidine (GEMCITABINE): a phase II study in patients with advanced breast cancer. Proc Am Soc Clin Oncol 12:A57, 1993
15. Moore DF, Jr, Pazdur R, Daugherty K, Tarassoff P, Abbruzzese JL: Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs 10(4):323-325, 1992
16. Fink U, Molle B, Daschner H, Ermisch S, Loffel J, Herrmann R: Phase II study of gemcitabine in metastatic colorectal cancer. Proc Am Soc Clin Oncol 11:A507, 1992
17. Abbruzzese J, Pazdur R, Ajani J, Daugherty K, Tarassoff P, Levin B: A phase II trial of gemcitabine (DFDC) in patients (pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 10:A456, 1991
18. Sessa C, Aamdal S, Wolff I, Eppelbaum R, Smyth JF, Sulkes A, Ten Bokkel Huinink W, Vermerken J, Wanders J, Franklin H: Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group. Ann Oncol 5(5):471-472, 1994
19. Christman K, Kelsen D, Saltz L, Tarassoff PG: Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 73(1):5-7, 1994
20. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J: A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5(6):543-547, 1994
21. Clavel M, Vermorken JB, Judson I, Wagener T, Hatty S, Wanders J: Gemcitabine in an active drug in patients with squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 11:A808, 1992
22. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 12(9):1821-1826, 1994
23. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12(8):1535-1540, 1994
24. Cormier Y, Eisenhauer E, Muldal G, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5(3):283-285, 1994
25. Anderson H, Thatcher N, Walling J, Lund B: Gemcitabine and palliation of symptoms in non-small cell lung cancer (NSCLS). Proc Am Soc Clin Oncol 13:A1238, 1994
26. Abratt R, Bezwoda W, Fankson G, Goedhals L, Hacking D, Rugg T: Efficacy and safety of gemcitabine in non-small cell lung cancer (NSCLC): phase II study results. Proc Am Soc Clin Oncol 12:A1130, 1993
27. Cormier Y, Eisenhauer E, Gregg R, Ayoub J, Goss G, Stewart D, Muldal A, Tarassoff P: Gemcitabine: an active new agent in patients (pts) with previously untreated small cell lung cancer (SCLC). A phase II trials of the NCI Canada Clinical Trials Group (NCIC CTG). Proc Am Soc Clin Oncol 12:A1097, 1993
28. Shephard FA, Gatzemeier U, Gotfried M, Weynants P, Cottier B, Groen H, Rosso R, Mattson K, Cortes-Funes H, Tonato M: An extended phase II study of gemcitabine in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 12:A1096, 1993
29. Thatcher N, Anderson H, Lund B, Hansen H: Gemcitabine in the treatment of non-small cell lung cancer. Ann Oncol 3(Suppl 5):198, 1992
30. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86(20):1530-1533, 1994
31. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP: Phase II study of gemcitabine in previously platinum-treated ovarian cancer (OC) patients (pts). An update. Proc Am Soc Clin Oncol 12:A834, 1993
32. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12(1):29-34, 1994
33. Carmichael J, Fink U, Russell RC, Spittle MF, Harris A, Spiessel G, Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 12:A698, 1993
34. Mertens WC, Eisenhauer EA, Moore M, Venner P, Stewart D, Muldal A, Wong D: Gemcitabine in advanced renal cell carcinoma. A phase II study of National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4(4):331-332, 1993
35. Weissbach L, de Mulder P, Osieka R, Ermisch S, Jakse G: Phase II study of gemcitabine in renal cancer. Proc Am Soc Clin Oncol 11:A689, 1992
36. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W: Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823-6829, 1990
37. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9(3):491-498, 1991